We have located links that may give you full text access.
Coverage of Congenital Anomalies: Ensuring Lasting Smiles Act (ELSA) in Legislation.
Plastic and Reconstructive Surgery 2024 March 5
The Ensuring Lasting Smiles Act (ELSA) is a federal bill which would require all health federally regulated insurance products to cover the full treatment of a congenital anomaly or birth defect until complete restoration of normal function or appearance. ELSA has been a key federal priority for the Legislative Advocacy Committee of the American Society of Plastic Surgeons (ASPS) since the 115 th Congress in 2018. Although it has gained momentum, particularly in the 117 th Congress, the bill remains stalled. Congressional Budget Office review, conducted in March 2022, appears to have overestimated this bill's cost for the private sector, secondary to an alleged lack of data on the prevalence of the conditions, extent of treatments and their costs, and the current extent of private sector coverage. The present review highlights the progress of the ELSA bill and serves to illustrate the hurdles involved in passing significant healthcare bills. This review emphasizes the need for healthcare professionals to provide their congressional representatives with accurate information on realistic cost of currently covered treatments of congenital defects, the necessary treatments not currently covered by insurance, and additional out-of-pocket costs covered by patients. A concerted effort by plastic surgeons should provide tools for ELSA legislative champions to re-introduce and pass the bill during the 118th Congress. This process highlights the essential role of organized medicine in advocating for the successful passage of healthcare legislation.
Full text links
Related Resources
Trending Papers
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.International Journal of Molecular Sciences 2024 May 2
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app